# ADV-TK Improves Outcome of Recurrent High-Grade Glioma

> **NCT00870181** · PHASE2 · COMPLETED · sponsor: **Huazhong University of Science and Technology** · enrollment: 47 (actual)

## Conditions studied

- Malignant Glioma of Brain
- Glioblastoma

## Interventions

- **BIOLOGICAL:** ADV-TK/GCV
- **PROCEDURE:** Surgery
- **DRUG:** systemic chemotherapy

## Key facts

- **NCT ID:** NCT00870181
- **Lead sponsor:** Huazhong University of Science and Technology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2011-12
- **Final completion:** 2012-12
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2013-06-25

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00870181

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00870181, "ADV-TK Improves Outcome of Recurrent High-Grade Glioma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00870181. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*